Related Experiment Video
Updated: Jul 12, 2025

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
Published on: February 23, 2024
Describing Self-Advocacy in Underrepresented Women With Advanced Cancer
Sarah Bell1, Rachel Bergeron2, Patricia Jo Murray2
1University of Pittsburgh Medical Center Magee-Womens Hospital.
Purpose:
To describe the self-advocacy experiences of women from underrepresented groups who have advanced breast or gynecologic cancer.
Participants & Setting:
To be eligible for the study, participants had to self-identify as vulnerable, which was defined as a member of a group considered at risk for poor cancer outcomes and underrepresented in clinical research.
Methodologic Approach:
This descriptive, longitudinal, qualitative study consisted of one-on-one interviews of women within three months of an advanced breast or gynecologic cancer diagnosis.
Findings:
10 participants completed 25 interviews. The average age of participants was 60.2 years (range = 38-75 years). Three major themes emerged: (a) speaking up and speaking out, (b) interacting with the healthcare team, and (c) relying on support from others.
Implications For Nursing:
Women with advanced cancer who are from underrepresented groups self-advocated in unique ways, learning over time the importance of how to communicate their needs and manage their healthcare team. Future research should incorporate these findings into tailored self-advocacy interventions.
Related Concept Videos
Nursing Ethical Principles II
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
Treatment Resistant Cancers
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancer Survival Analysis
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

